ROL — Rollins, Inc.

The market's mood turned sharply negative on the Q2 2026 print: adjusted EPS of $0.32 vs. $0.34 expected, revenue of $1.078B (up 7.9% YoY but ~$10M light), and management cutting FY2026 organic revenue growth guidance to "at least 6%" citing softer digital lead generation in residential pest control, plus margin compression from medical and fuel costs. Sell-side followed: Wells Fargo downgraded to Underweight, JPMorgan to Neutral with its target cut from $70 to $45, and Barclays/BNP targets moved down to the $44-45 area; consensus is now a Hold with a $49 mean target but a $44.56 more recent average. Layered on top, Pomerantz announced a securities-fraud investigation in late August 2026. As of 2026-09-13 the tape reflects all of this: -3.15% over one week, -4.9% over one month, -26.4% over three months and -37.0% over six months, with the price 32.9% below its 200-day average.

Revenue growth is decelerating but has not broken: YoY comparisons ran +12.1% (Q2 2025), +12.0% (Q3 2025), +9.7% (Q4 2025), +10.2% (Q1 2026), then +7.9% in Q2 2026 ($1,078.6M vs. $999.5M) — a genuine step down, consistent with the guidance cut to "at least 6%" organic. Margins have inflected the wrong way in the two most recent quarters: Q2 2026 operating margin of 18.7% is 117bp below Q2 2025's 19.8%, and Q1 2026's 16.1% was 129bp below Q1 2025's 17.3%, after Q3 2025 actually expanded to 21.9% from 20.9%. EPS is still grinding up (Q2 2026 $0.30 vs. $0.29; TTM diluted EPS $1.105), but free cash flow has flattened — TTM FCF of $619.2M versus FY2025's $650.0M, with Q1 2026 FCF of $111.2M down 20.6% YoY. Net read: this is a deceleration and a real margin squeeze, not a structural collapse — commercial (+7.2%) and termite (+8.9%) remain solid, and the softness is concentrated in residential digital lead generation, which is cyclical/consumer-linked rather than a broken business model.

As of 2026-09-13 the stock trades at 31.6x TTM earnings ($1.105 EPS) and roughly 30.4x next-FY consensus EPS of $1.142, with a PEG of 3.54, P/S of 4.26 (vs. a 5-year average of 6.99) and P/B of 11.7. Against its own 5-year average P/E of 49.7x it screens cheap — the deterministic overlay scores that comparison 97.2/100 — but that historical average was built in a near-zero-rate, premium-multiple era, so the "cheap" label is relative, not absolute. At ~30x forward earnings for 6-8% growth, ROL is still a premium-multiple stock versus the broad market; it is fairly valued at best, not a bargain. The case for the multiple is quality: 20.9% ROIC, 50.7% gross margin, 13.6% net margin, and highly recurring, non-discretionary revenue.

As of 2026-09-13, the story in the price is a multiple de-rating, not an earnings collapse: earnings are still growing while the multiple has compressed from the ~50x range toward ~30x. That means the stock is now priced for a permanent growth haircut to roughly 6% organic, but not for an actual earnings decline. The bear path is further estimate slippage — consensus next-FY EPS of $1.142 already embeds only about 6% growth off FY2026, and the low analyst target of $32 implies a mid-20s multiple on that number, so there is still downside if the residential weakness proves structural. The bull path is multiple re-expansion on stabilization: if residential lead volumes normalize and margins stop compressing, low-double-digit EPS growth plus a 33-35x multiple gets you to $38-40 without heroic assumptions. The Q3 2026 report (late October to early November 2026) is the first hard evidence either way, so near-term price action is likely to be event-driven around earnings rather than trend-driven.

As of 2026-09-13, RSI(14) was 31.06 — approaching oversold but not at the capitulation extremes that usually mark durable lows — with the price 3.4% below its 20-day SMA, 10.71% below its 50-day SMA and 32.93% below its 200-day SMA. That is a textbook downtrend: every moving average is above the price and the 200-day gap is unusually wide, meaning the stock is extended to the downside but has shown no base-building yet. At $34.73 versus a 52-week low of $34.35, ROL is grinding along the bottom of its range on weak momentum (-3.15% 1wk, -4.9% 1mo). Implication: oversold bounce risk is real and short-covering rallies toward the $38-40 area are plausible, but there is no technical confirmation of a turn — a reclaim of the 20-day SMA with RSI back above 40 would be the first real signal. Practically, that argues for scaling in on weakness rather than a single full position, and for treating the pre-earnings drift as noise.

• Housing turnover and rates: elevated mortgage rates and frozen existing-home sales suppress moving-related residential pest and termite demand, which feeds directly into the softer digital lead volumes that drove the guidance cut; a rate-cutting cycle would be a clear tailwind.
• Consumer discretionary pressure: residential pest control has a discretionary/upgrade component, and stretched household budgets reduce inbound digital lead conversion even where recurring contract revenue holds.
• Cost inflation: rising employee medical benefits and fuel/logistics costs are the explicitly named drivers of the 117-129bp YoY operating margin compression in the last two reported quarters, with technician wage inflation an ongoing structural cost.
• Labor availability: technician recruiting and retention is the binding constraint on service capacity and organic growth in pest control, and it is a cost line that rarely deflates.
• Defensive sector positioning: with a 0.736 beta and non-discretionary, regulatory-driven commercial demand, ROL is a classic defensive holding that tends to lag in risk-on rotations and attract flows when growth scares hit — a factor in both the de-rating and any eventual recovery.

• Q3 2026 earnings (expected late October to early November 2026): the single most important datapoint — evidence on whether residential digital lead volumes are stabilizing, whether cost-realignment under new CFO William Harkins is biting, and whether the "at least 6%" organic guidance is reaffirmed or cut again.
• Margin trajectory: proof the company can defend its historical ~25% EBITDA margin against medical and fuel inflation; two more quarters of YoY compression would validate the bear case.
• Bolt-on M&A cadence and pricing power: continued disciplined acquisitions plus the annual price increase are the main levers to re-accelerate reported growth back toward double digits.
• Resolution of the Pomerantz securities investigation announced in late August 2026 — a clean outcome removes an overhang; an escalation adds headline risk.
• A rate-cut/housing-turnover recovery, which would lift residential lead generation without any company-specific execution improvement.

• The residential deceleration proves structural rather than cyclical (share loss to competitors such as Rentokil, regional operators or DIY/online alternatives), which would break the long-term compounding story rather than just dent a year.
• Continued consensus EPS downgrades; next-FY consensus of $1.142 already bakes in only ~6% growth, and the $32 low analyst target implies further multiple and estimate compression.
• Margin erosion that persists — Q2 2026 operating margin 18.7% vs. 19.8% a year earlier and Q1 2026 16.1% vs. 17.3% is a two-quarter pattern, not a one-off.
• Securities litigation risk following the late-August 2026 Pomerantz investigation into whether management misled investors about residential demand prior to the Q2 miss.
• Balance sheet optics: current ratio of 0.629 with $938M of current liabilities against $590M of current assets looks thin (mitigated by the fact that a chunk of that is deferred revenue collected up front), and D/E of 0.78 with $487M of long-term debt leaves less room than the pristine-multiple era implied.

Rollins is a genuinely high-quality, non-discretionary, capital-light compounder — 20.9% ROIC, 50.7% gross margin, $619M of TTM free cash flow and a negative accruals ratio confirming cash is running ahead of reported earnings — that has been de-rated from the ~50x range to roughly 30x forward earnings after one soft quarter of residential lead generation. The de-rating has done most of the work: at $34.73 on 2026-09-13 the stock sits near my independently calculated fair value of about $36, so this is no longer stretched, but it is also not a bargain — you are paying a full multiple for a business growing 6-8% with compressing margins. Honest read: a quality name to accumulate on further weakness or on the first evidence of stabilization, not a screaming buy at this price, with Q3 2026 as the pivotal event.

Simplified DCF on TTM free cash flow of $619.2M (Q3 2025-Q2 2026) growing 7% for five years with a 3.5% terminal rate and a ~7.8-8.0% WACC (beta 0.736, debt only ~2.8% of capital, net debt $378M) gives roughly $33.7/share; a justified-P/E cross-check using a 30-31x multiple on next-FY EPS of $1.142 (supported by a Gordon-growth implied multiple of ~31x from a ~62% payout, 8% required return and 6% sustainable growth) gives $34-35; I blend these and shade modestly higher for the 20.9% ROIC and recurring-revenue quality to land at $36.00, roughly 4% above the 2026-09-13 price of $34.73.